Management of Chronic Epstein-Barr Virus Infection with Associated Autoimmune Disorders

Diagnostic Approach

Diagnosis of chronic active EBV disease requires persistent or recurrent symptoms including fever, lymphadenopathy, and/or hepatosplenomegaly for more than 3 months, according to the American Journal of Hematology 1, 2
Elevated EBV antibody titers, typically including VCA-IgG ≥1:640 and EA-IgG ≥1:160, are a key diagnostic criterion, as recommended by the American Journal of Hematology 1, 2

Hematopoietic stem cell transplantation is considered the only curative treatment for severe CAEBV and should be pursued when available, as stated by the American Journal of Hematology 3
Reduction of immunosuppression should be considered when possible in patients on immunomodulatory therapy, according to the Journal of Crohn's and Colitis 4
Rituximab is recommended for significant EBV DNA-emia, with a dosage of 375 mg/m², once weekly for 1-4 doses, as recommended by Haematologica 5

Treatment of specific autoimmune manifestations should follow standard protocols for each condition, as recommended by the Journal of Allergy and Clinical Immunology 6
Autoimmune cytopenias, such as thrombocytopenia and hemolytic anemia, require specific interventions, according to the Journal of Allergy and Clinical Immunology 6

Patients on thiopurines have an increased risk of EBV-associated lymphoproliferative disorders, as reported by the Journal of Crohn's and Colitis 7, 4
Primary EBV infection during immunosuppressive therapy poses a particular risk, and temporary discontinuation of immunomodulators during acute infection should be considered, as recommended by the Journal of Crohn's and Colitis 7, 4

Rituximab is the treatment of choice for EBV-associated lymphoproliferative disorders, as stated by Haematologica 5
Reduction of immunosuppression should be combined with rituximab when possible, as recommended by Haematologica 5
Discontinuation of immunosuppressive therapy may result in spontaneous regression of EBV-associated lymphoproliferative disease in some cases, according to the Journal of Crohn's and Colitis 4

The American Society of Hematology recommends that CAEBV requires markedly elevated titers (VCA-IgG ≥1:640 and EA-IgG ≥1:160) along with persistent symptoms for more than 3 months, including fever, lymphadenopathy, and hepatosplenomegaly 8
EBV DNA levels >102.5 copies/mg DNA in peripheral blood mononuclear cells support a diagnosis of CAEBV when combined with appropriate clinical features 8

Assess for IM-like symptoms: persistent fever, significant lymphadenopathy, hepatosplenomegaly, or complications affecting hematologic, hepatic, neurologic, pulmonary, or cardiovascular systems 8
Consider EBV DNA quantification in cases of persistent fever and fatigue to evaluate for possible EBV reactivation, though this is not routinely recommended 9, 10

The European Hematology Association recommends that antiviral drugs are not recommended for chronic fatigue with elevated EBV antibodies, as they do not impact disease progression or symptoms in the absence of true CAEBV 11
Rituximab 375 mg/m² once weekly for 1-4 doses is recommended for significant EBV DNA-emia until viral load negativity 11

In immunocompromised patients, different thresholds and management strategies apply, with rituximab indicated for significant EBV DNA-emia even without full CAEBV criteria 9, 11, 12

The American Journal of Hematology recommends confirming the diagnosis of CAEBV by meeting all three criteria: persistent or recurrent infectious mononucleosis-like symptoms, markedly elevated EBV antibody titers, and confirmation of EBV-infected T or NK cells in affected tissues 13, 14, 15
The American Journal of Hematology suggests that markedly elevated EBV antibody titers include VCA-IgG ≥1:640 and EA-IgG ≥1:160, and/or EBV DNA ≥10,000 IU/mL in whole blood 13

The American Journal of Hematology recommends proceeding to allogeneic HSCT as soon as disease is adequately controlled, with a 3-year overall survival rate of 87.3% 16

The American Journal of Hematology notes that severe hypercytokinemia and hemophagocytic syndrome can occur suddenly and result in fatal outcomes, requiring aggressive immunosuppression and urgent consideration for HSCT 17, 18

The American Journal of Hematology identifies poor prognostic indicators, including late onset of disease, thrombocytopenia, EBV infection of T cells, and chromosomal abnormalities in the 6q region 15, 17, 18

The American Journal of Hematology advises against using "CAEBV" terminology if an underlying lymphoma or specific lymphoproliferative disorder is identified pathologically, and instead recommends using the specific disease name 17, 18, 19